XJ 103
Alternative Names: XJ-103Latest Information Update: 29 Sep 2023
At a glance
- Originator Starmab Biologics Shanghai
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Streptococcal infections
Most Recent Events
- 12 Sep 2023 Pharmacodynamics data from a preclinical study in Streptococcal infections released by Starmab Biologics Shanghai
- 07 Sep 2023 Preclinical trials in Streptococcal infections in China (Parenteral) (Starmab Biologics Shanghai website, September 2023)
- 28 Jun 2023 Starmab Biologics plans to file an IND application with the NMPA in for Streptococcal infections in 2023